Hansjakob Furrer
YOU?
Author Swipe
View article: Population pharmacokinetics of bictegravir in real-world people with HIV
Population pharmacokinetics of bictegravir in real-world people with HIV Open
Objectives Bictegravir is an integrase strand transfer inhibitor widely prescribed due to its good efficacy and safety profile. Its pharmacokinetic (PK) profile has not been described in real-world settings yet. This study aimed to charact…
View article: Low Trauma Fractures in People With HIV: Longitudinal Time Trends in the Swiss HIV Cohort Study, 2009–2022
Low Trauma Fractures in People With HIV: Longitudinal Time Trends in the Swiss HIV Cohort Study, 2009–2022 Open
Background People with human immunodeficiency virus (HIV) are at increased risk of low trauma fractures (LTFs). Published data on LTF incidence trends over time have not been uniform. This study sought to analyze LTF time trends in the Swi…
View article: Types of Myocardial Infarction in People With HIV in Switzerland
Types of Myocardial Infarction in People With HIV in Switzerland Open
Background Of myocardial infarctions (MIs) recorded in 2 large human immunodeficiency virus (HIV) observational studies from North America, approximately half were classified as type 2. In the REPRIEVE clinical trial of pitavastatin versus…
View article: Machine Learning-based Prediction of Active Tuberculosis in People With HIV Using Clinical Data
Machine Learning-based Prediction of Active Tuberculosis in People With HIV Using Clinical Data Open
Background Coinfections of Mycobacterium tuberculosis (MTB) and human immunodeficiency virus (HIV) impose a substantial global health burden. Patients with MTB infection face a heightened risk of progression to incident active TB, which pr…
View article: HIV-1 Low-Level Viremia Predicts Viral Failure in Participants on Antiretroviral Therapy in the Swiss HIV Cohort Study
HIV-1 Low-Level Viremia Predicts Viral Failure in Participants on Antiretroviral Therapy in the Swiss HIV Cohort Study Open
Background Most individuals receiving combination antiretroviral therapy (ART) have human immunodeficiency virus (HIV) plasma viral loads below the limit of detection. However, episodes of low-level viremia (LLV) are observed in subsets of…
View article: HIV replication and tuberculosis risk among people living with HIV in Europe: A multicohort analysis, 1983–2015
HIV replication and tuberculosis risk among people living with HIV in Europe: A multicohort analysis, 1983–2015 Open
Introduction HIV replication leads to a change in lymphocyte phenotypes that impairs immune protection against opportunistic infections. We examined current HIV replication as an independent risk factor for tuberculosis (TB). Methods We in…
View article: Application of the estimand framework for an emulated trial using reference based multiple imputation to investigate informative censoring
Application of the estimand framework for an emulated trial using reference based multiple imputation to investigate informative censoring Open
Background The ICH E9 (R1) addendum on Estimands and Sensitivity analysis in Clinical trials proposes a framework for the design and analysis of clinical trials aimed at improving clarity around the definition of the targeted treatment eff…
View article: External Validation of Serologic Scores for the Detection of Liver Steatosis Among People With HIV
External Validation of Serologic Scores for the Detection of Liver Steatosis Among People With HIV Open
Background Fatty liver index (FLI) and hepatic steatosis index (HSI) are serologic scores used to detect liver steatosis. However, their diagnostic performance in people with HIV (PWH) remains unclear. We performed an external validation o…
View article: Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study
Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study Open
Background Bivalent messenger RNA (mRNA) vaccines, designed to combat emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, incorporate ancestral strains and a new variant. Our study assessed the immune response i…
View article: Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy
Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy Open
Background We evaluated long-term trajectories of circulating hepatitis B virus (HBV) RNA and hepatitis B core–related antigen (HBcrAg) in persons with and without hepatitis B surface antigen (HBsAg) loss during tenofovir therapy in the Sw…
View article: Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide (TAF) in People With Human Immunodeficiency Virus (HIV)
Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide (TAF) in People With Human Immunodeficiency Virus (HIV) Open
Background Antiretroviral therapy (ART)-related weight gain is of particular concern in people with HIV (PWH). Although weight gain was observed among PWH receiving tenofovir alafenamide (TAF), little is known about the potential reversibi…
View article: Population Pharmacokinetics of Cabotegravir Following Oral Administration and <scp>Long‐Acting</scp> Intramuscular Injection in <scp>Real‐World</scp> People with <scp>HIV</scp>
Population Pharmacokinetics of Cabotegravir Following Oral Administration and <span>Long‐Acting</span> Intramuscular Injection in <span>Real‐World</span> People with <span>HIV</span> Open
Long‐acting cabotegravir has been studied mainly in the stringent framework of clinical trials, which does not necessarily reflect the situation of people with HIV (PWH) in routine clinical settings. The present population pharmacokinetic …
View article: Deciphering Factors Linked With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Susceptibility in the Swiss HIV Cohort Study
Deciphering Factors Linked With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Susceptibility in the Swiss HIV Cohort Study Open
Background Factors influencing susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain to be resolved. Using data from the Swiss HIV Cohort Study on 6270 people with human immunodeficiency virus (HIV) and sero…
View article: Time Trends in Causes of Death in People With HIV: Insights From the Swiss HIV Cohort Study
Time Trends in Causes of Death in People With HIV: Insights From the Swiss HIV Cohort Study Open
Background Advancements in access to antiretroviral therapy (ART) and human immunodeficiency virus (HIV) care have led to a decline in AIDS-related deaths among people with HIV (PWH) in Switzerland. However, data on the ongoing changes in …
View article: Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland
Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland Open
This work was funded by the Swiss National Science Foundation, grant number N◦ 324730_192449. This study received no support from pharmaceutical industries. This study was performed within the framework of the Swiss HIV Cohort Study, suppo…
View article: Brief Report: Decreased Physical Activity and Prolonged Sitting Time Are Associated With Liver Steatosis in People With HIV
Brief Report: Decreased Physical Activity and Prolonged Sitting Time Are Associated With Liver Steatosis in People With HIV Open
Background: Physical activity (PA) regulates intrahepatic storage of fat and reduces the risk of liver steatosis. Given our limited understanding of the pathogenesis of metabolic complications in people with HIV (PWH), it remains unclear w…
View article: Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2)
Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2) Open
Background After basic immunization with 2 mRNA SARS-CoV-2 vaccine doses, only a small proportion of patients who are severely immunocompromised generate a sufficient antibody response. Hence, we assessed the additional benefit of a third …
View article: Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV): A Study Combining Modelling and Swiss HIV Cohort Data
Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV): A Study Combining Modelling and Swiss HIV Cohort Data Open
Background Obesity is increasingly prevalent among people with HIV (PWH) and can possibly result in suboptimal antiretroviral drug (ARV) exposure and response. However, this has not been thoroughly evaluated given that obese PWH are underr…
View article: Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018
Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018 Open
Background Genotypic resistance testing (GRT) is routinely performed upon diagnosis of HIV-1 infection or during virological failure using plasma viral RNA. An alternative source for GRT could be cellular HIV-1 DNA. Objectives A substantia…
View article: PB2574: HEMOPHAGOCYTIC SYNDROME IN ADULTS - REAL-WORLD DATA ON MORTALITY FROM A TERTIARY REFERENCE CENTER
PB2574: HEMOPHAGOCYTIC SYNDROME IN ADULTS - REAL-WORLD DATA ON MORTALITY FROM A TERTIARY REFERENCE CENTER Open
Topic: 30. Infections in hematology (incl. supportive care/therapy) Background: Hemophagocytic Syndrome (HLH) is a rare, life-threatening condition characterized by hyperinflammatory response associated with aberrant macrophages activation…
View article: Sexual Behaviour and STI Incidence in Sexually Active MSM Living With HIV in Times of COVID-19
Sexual Behaviour and STI Incidence in Sexually Active MSM Living With HIV in Times of COVID-19 Open
Despite decreased numbers of sexual partners, the COVID-19 pandemic had limited impact on the prevalence of attending private sex parties, traveling for sex within Switzerland, and practicing chemsex in men with HIV who have sex with men. …
View article: <i>Mycobacterium tuberculosis</i>infection associated immune perturbations correlate with antiretroviral immunity
<i>Mycobacterium tuberculosis</i>infection associated immune perturbations correlate with antiretroviral immunity Open
Infection with Mycobacterium tuberculosis (MTB) remains one of the most important opportunistic infections in people with HIV-1 (PWH). While active Tuberculosis (TB) leads to rapid progression of immunodeficiency in PWH, the interaction be…
View article: Understanding the Decline of Incident, Active Tuberculosis in People With Human Immunodeficiency Virus in Switzerland
Understanding the Decline of Incident, Active Tuberculosis in People With Human Immunodeficiency Virus in Switzerland Open
Background People with human immunodeficiency virus type 1 (HIV-1) (PWH) are frequently coinfected with Mycobacterium tuberculosis (MTB) and at risk for progressing from asymptomatic latent TB infection (LTBI) to active tuberculosis (TB). …
View article: Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy
Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy Open
Background Integrase strand transfer inhibitors (INSTIs) have been associated with an increased risk for cardiovascular disease (CVD) events. We investigated the impact of starting INSTI-based antiretroviral therapy (ART) on CVD events amo…
View article: Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)
Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2) Open
Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%–98.7%]) compared to Pfizer-Bio…
View article: Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection
Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection Open
Among adults with CD4+ counts >500 cells/mm3, excess risk of AIDS and SNA associated with delaying treatment initiation was diminished after ART initiation, but persistent excess risk remained. (Funded by the National Institute of Allergy …